Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Bio-inspired consolidants derived from crystalline nanocellulose for decayed wood.

Basile R, Bergamonti L, Fernandez F, Graiff C, Haghighi A, Isca C, Lottici PP, Pizzo B, Predieri G.

Carbohydr Polym. 2018 Dec 15;202:164-171. doi: 10.1016/j.carbpol.2018.08.132. Epub 2018 Aug 31.

PMID:
30286989
2.

Cerebral NIRS patterns in late preterm and very preterm infants becoming late preterm.

Grometto A, Pizzo B, Strozzi MC, Gazzolo F, Gazzolo D.

J Matern Fetal Neonatal Med. 2019 Apr;32(7):1124-1129. doi: 10.1080/14767058.2017.1401605. Epub 2017 Nov 20.

PMID:
29157051
3.

Near-infrared spectroscopy is a promising noninvasive technique for monitoring the effects of feeding regimens on the cerebral and splanchnic regions.

Grometto A, Pizzo B, Strozzi MC, Gazzolo F, Gazzolo D.

Acta Paediatr. 2018 Feb;107(2):234-239. doi: 10.1111/apa.14099. Epub 2017 Oct 24.

PMID:
28960522
4.

Advantages and Disadvantages of Pediatric Sedation in Magnetic Resonance Imaging.

Del Pizzo B.

Radiol Technol. 2016 Jan-Feb;87(3):329-32. No abstract available.

PMID:
26721842
5.

Quantitative evaluation by attenuated total reflectance infrared (ATR-FTIR) spectroscopy of the chemical composition of decayed wood preserved in waterlogged conditions.

Pizzo B, Pecoraro E, Alves A, Macchioni N, Rodrigues JC.

Talanta. 2015 Jan;131:14-20. doi: 10.1016/j.talanta.2014.07.062. Epub 2014 Aug 1.

PMID:
25281067
6.

Comparative study of Fourier transform infrared spectroscopy in transmission, attenuated total reflection, and total reflection modes for the analysis of plastics in the cultural heritage field.

Picollo M, Bartolozzi G, Cucci C, Galeotti M, Marchiafava V, Pizzo B.

Appl Spectrosc. 2014;68(4):389-96. doi: 10.1366/13-07199.

PMID:
24694694
8.

Durability of five native Argentine wood species of the genera Prosopis and Acacia decayed by rot fungi and its relationship with extractive content.

Pometti CL, Palanti S, Pizzo B, Charpentier JP, Boizot N, Resio C, Saidman BO.

Biodegradation. 2010 Sep;21(5):753-60. doi: 10.1007/s10532-010-9340-5. Epub 2010 Feb 27.

PMID:
20195704
9.

Argentinean native wood species: Physical and mechanical characterization of some Prosopis species and Acacia aroma (Leguminosae; Mimosoideae).

Pometti CL, Pizzo B, Brunetti M, Macchioni N, Ewens M, Saidman BO.

Bioresour Technol. 2009 Mar;100(6):1999-2004. doi: 10.1016/j.biortech.2008.09.061. Epub 2008 Dec 2.

PMID:
19054667
10.

Patch test triggering recurrence of distant dermatitis: the flare-up phenomenon.

Torchia D, Capretti C, Pizzo B, Francalanci S.

CMAJ. 2008 Aug 12;179(4):341. doi: 10.1503/cmaj.080636. No abstract available.

11.

Practice does make perfect. A longitudinal look at repeated taste exposure.

Williams KE, Paul C, Pizzo B, Riegel K.

Appetite. 2008 Nov;51(3):739-42. doi: 10.1016/j.appet.2008.05.063. Epub 2008 Jun 8.

PMID:
18585415
12.

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.

Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM.

J Thorac Oncol. 2007 Jul;2(7):638-44.

13.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.

Milton DT, Riely GJ, Azzoli CG, Gomez JE, Heelan RT, Kris MG, Krug LM, Pao W, Pizzo B, Rizvi NA, Miller VA.

Cancer. 2007 Aug 1;110(3):599-605.

14.

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM.

Clin Cancer Res. 2007 May 1;13(9):2692-8.

15.

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA.

Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75. Epub 2006 Aug 1.

PMID:
16896930
16.

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.

Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, Kris MG, Heelan RT, Pizzo B, Tyson L, Sheehan C, Ross JS, Venkatraman E.

Cancer. 2005 Nov 15;104(10):2149-55.

17.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.

Cancer. 2005 May 15;103(10):2128-31.

18.

Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA.

J Clin Oncol. 2005 Jan 1;23(1):165-74. Epub 2004 Nov 22.

PMID:
15557594
19.

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100.

20.

New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.

Pizzo B.

Clin J Oncol Nurs. 2004 Aug;8(4):385-92. Review.

PMID:
15354925
21.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT.

J Clin Oncol. 2004 Mar 15;22(6):1103-9.

PMID:
15020612
22.

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO.

Clin Cancer Res. 2004 Feb 1;10(3):916-23.

23.

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM.

Clin Cancer Res. 2003 Jun;9(6):2072-8.

24.

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J.

J Clin Oncol. 2003 Jun 1;21(11):2094-100.

PMID:
12775734
25.

Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.

Krug LM, Miller VA, Kalemkerian GP, Kraut MJ, Ng KK, Heelan RT, Pizzo BA, Perez W, McClean N, Kris MG.

Ann Oncol. 2000 Feb;11(2):227-8. No abstract available.

PMID:
10761761
26.

Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer.

Miller VA, Krug LM, Ng KK, Pizzo B, Perez W, Heelan RT, Kris MG.

J Clin Oncol. 2000 Mar;18(6):1346-50.

PMID:
10715307
27.

Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma.

Miller VA, Ng KK, Krug LM, Perez W, Pizzo B, Heelan RT, Kris MG.

Cancer. 2000 Mar 1;88(5):1045-50.

PMID:
10699893
28.

Oral cisapride for the control of delayed vomiting following high-dose cisplatin.

Pizzo BA, Pisters KM, Miller VA, Grant SC, Baltzer L, Hinckley L, Kris MG.

Support Care Cancer. 1999 Jan;7(1):44-6.

PMID:
9926974
29.

Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.

Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG.

Ann Oncol. 1997 Dec;8(12):1269-71.

PMID:
9496394
30.
31.

Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ.

J Natl Cancer Inst. 1997 Jun 4;89(11):817-8. No abstract available.

PMID:
9182982
32.

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.

Kris MG, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V, Ferguson BB, Allman DS, Pizzo BA, Baker TW, Fernando IJ, Chernoff SB.

J Clin Oncol. 1997 May;15(5):2135-8.

PMID:
9164228
33.

Nurses can learn to manage the unique side effects and adverse reactions associated with docetaxel.

Pizzo B, Houlihan N.

Oncol Nurs Forum. 1997 Jan-Feb;24(1):22. No abstract available.

PMID:
9007899

Supplemental Content

Support Center